

2021 EFPIA DISCLOSURE (inc. Vaccines Europe)												
Date of publication: 27th of June 2022												
	Full Name	HCPs: City of Principal Practice HCOs: city where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL	Donations and Grants to HCOs and POs	Contribution to costs of Events			Fee for service and consultancy		
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees excl. VAT	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation related to the	
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up; itemization should be available for the individual recipient or public authorities' consultation only, as											
	Inger Marie Ljøes	HUS	Norway	Haukeland University Hospital, Bergen		N/A	N/A				15.000	
						N/A	N/A					
						N/A	N/A					
						N/A	N/A					
						N/A	N/A					
						N/A	N/A					
						N/A	N/A					
						N/A	N/A					
						N/A	N/A					
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A					
Number of Recipients in aggregate disclosure						N/A	N/A					
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A					
HCOs	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up; itemization should be available for the individual recipient or public authorities' consultation only, as											
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A					
Number of Recipients in aggregate disclosure						N/A	N/A					
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A					
POs	INDIVIDUAL NAMED DISCLOSURE - one line per PO (i.e. all transfers of value during a year for an individual PO will be summed up; itemization should be available for the individual recipient or public authorities' consultation only, as appropriate)											
	Onkologisk Forum Norge			Grant to support the meeting the 18-19th of November 2021		20.000 NOK						
OTHER, NOT INCLUDED ABOVE - where information cannot be disclosed on an individual basis for legal reasons												
Aggregate amount attributable to transfers of value to such Recipients						N/A	N/A					
Number of Recipients in aggregate disclosure						N/A	N/A					
% of the number of Recipients included in the aggregate disclosure in the total number, by category, of Recipients disclosed						N/A	N/A					
AGGREGATE DISCLOSURE												
Transfers of Value re Research & Development as defined												
N/A												